Nasdaq6d
INNOVATE Corp. Announces FDA Approval of MediBeacon® Transdermal GFR System for Kidney Function Assessment
The FDA has approved MediBeacon®'s TGFR system for noninvasive kidney function assessment, targeting both normal and impaired renal patients. INNOVATE Corp. announced the FDA approval of the ...
Nasdaq6d
FDA Approves AstraZeneca's Calquence For Patients With Untreated Mantle Cell Lymphoma
(RTTNews) - AstraZeneca (AZN), on Friday, announced that the FDA has approved CALQUENCE in ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...
Nasdaq5d
FDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast Cancer
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Nasdaq6d
Amgen's Lumakras+Vectibix Combo Gets FDA Approval For Metastatic Colorectal Cancer Treatment
Currently, Amgen's stock is trading at $272.83, up 1.26 percent on the Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those ...
Nasdaq6d
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
ITCI has also filed a supplemental new drug application (sNDA) to the FDA seeking approval of Caplyta as an adjunctive treatment for major depressive disorder. Additional phase III studies are ...
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook
Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...
Atara extends losses after FDA clinical hold
Atara Biotherapeutics (ATRA) stock slips as company faces an FDA clinical hold after rejection of lead candidate Ebvallo.
AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating
AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.
Ionis stock rises on FDA, EMA nod for SMA drug dose increase
Investing.com -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a ...
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation ...
Replimune stock soars on FDA priority review for melanoma treatment
Shares of Replimune Group, Inc. (NASDAQ: NASDAQ: REPL) surged 17% following the announcement that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...
Hosted on MSN5h
Beta Bionics joins IPO uptick, aims to raise $114.4m in Nasdaq listing
Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now set its financial goalposts, aiming to raise $114.4m from the initial public ...